Healthcare - Sector
CHRS is currently covered by 1 analysts with an average price target of $7. This is a potential upside of $6.63 (1791.89%) from yesterday's end of day stock price of $0.37.
Our record on Coherus BioSciences covers 16 analysts since 2008; 1 covers it today. Of the 90 price targets those analysts set on CHRS, 9 were reached (10%). The highest performance score on Coherus BioSciences belongs to Ashwani Verma of UBS: 6.25, with 2 of 3 targets met in 9 days on average. The latest calls: Jason Kolbert of Dawson James cut the target to $7 from $11 with a Buy rating on 5 Feb 2026; Jason Mccarthy of Maxim Group set a target of $4 with a Hold rating on 4 Sep 2025; Douglas Tsao of H.C. Wainwright updated the call with a Buy rating on 29 Apr 2025. Figures as of 18 Nov 2026.
Coherus BioSciences's activity chart (see below) currently has 137 price targets and 113 ratings on display. The stock rating distribution of CHRS is 100% BUY.
Analysts' price targets on this stock were met 13.57% of the time, taking 62.83 days on average.
Highest price target for CHRS is $7, Lowest price target is $7, average price target is $7.
Most recent stock forecast was given by JASON KOLBERT from DAWSON JAMES on 05-Feb-2026. First documented stock forecast 20-Jan-2016.
Currently out of the existing stock ratings of CHRS, 1 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Aug-2018
$7
$5.99 (593.07%)
$11
9 months 16 days ago
(05-Feb-2026)
0/3 (0%)
$4.91 (234.93%)
Hold Since 04-Sep-2025
$4
1 years 2 months 17 days ago
(04-Sep-2025)
3/10 (30%)
$2.69 (205.34%)
181
Buy Since 07-May-2019
1 years 6 months 23 days ago
(29-Apr-2025)
0/16 (0%)
$5.29 (309.36%)
Hold Since 24-Apr-2025
$1.05
1 years 6 months 28 days ago
(24-Apr-2025)
2/3 (66.67%)
$0.04 (3.96%)
9
Buy Since 23-Jan-2024
$6
1 years 11 months 16 days ago
(05-Dec-2024)
0/3 (0%)
$4.49 (297.35%)
What is CHRS (Coherus BioSciences) average time for price targets to be met?
Which analyst most recently updated their price target on CHRS (Coherus BioSciences)?
Which analyst has the most public recommendations on CHRS (Coherus BioSciences)?
Which analyst is the currently most bullish on CHRS (Coherus BioSciences)?
Which analyst is the currently most reserved on CHRS (Coherus BioSciences)?